Welcome to our dedicated page for Immix Biopharma SEC filings (Ticker: IMMX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Reading Immix Biopharma’s SEC disclosures often means scrolling through patent tables, multi-arm trial protocols and complex licensing clauses—information you need, but buried in hundreds of pages. If you have ever searched for “Immix Biopharma insider trading Form 4 transactions” or struggled to locate the latest oncology trial costs in a 10-K, you know the challenge.
Stock Titan solves that problem. Our AI instantly converts every Immix Biopharma quarterly earnings report 10-Q filing, 8-K material event, and proxy statement into clear language, highlighting where cash burn is trending and which milestones trigger future funding. With real-time EDGAR feeds, you receive Immix Biopharma Form 4 insider transactions real-time alerts, plus side-by-side charts that explain dilution risk and clinical spend—no spreadsheet gymnastics required.
Use this page to:
- Scan Immix Biopharma annual report 10-K simplified summaries to understand pipeline progress and orphan-drug incentives.
- Dive into Immix Biopharma 8-K material events explained for rapid updates on FDA designations and capital raises.
- Monitor Immix Biopharma executive stock transactions Form 4 before pivotal data read-outs.
- Read Immix Biopharma earnings report filing analysis that connects trial expenses to runway forecasts.
Whether you are comparing CAR-T competitors or simply understanding Immix Biopharma SEC documents with AI, our platform keeps every filing accessible, searchable, and context-rich—so you can focus on making informed biotech decisions, not deciphering legalese.
Immix Biopharma held its 2025 Annual Meeting on June 20, with 72.1% of voting shares represented (20,092,566 shares). Two key proposals were voted upon:
1. Board of Directors Election:
- All eight directors were successfully elected with strong majority support
- Ilya Rachman (CEO), Gabriel Morris, and Jason Hsu received notably high approval rates above 14.3M votes each
- Helen C. Adams and Carey Ng received relatively lower but still substantial support with approximately 13.3-13.6M votes
2. Auditor Appointment:
- Shareholders overwhelmingly approved Crowe LLP as independent auditor for FY2025
- The resolution passed with 19.9M votes in favor (99.3% approval), only 47,622 against, and 98,438 abstentions
The company is classified as an emerging growth company and trades on Nasdaq under symbol IMMX.
Carey Ng, Director of Immix Biopharma (IMMX), reported significant insider trading activity on June 20, 2025. The key transactions include:
- Acquisition of a stock option grant for 33,000 shares with an exercise price of $2.24, expiring June 20, 2035
- The options will vest in 12 equal monthly installments following the grant date, contingent on continued Board service
- Current holdings include 20,000 shares held directly and 1,025,221 shares held indirectly through Mesa Verde Venture Partners III, LP
As Managing Director of Mesa Verde Venture Partners III, LP, Ng has voting and dispositive power over the fund's holdings but disclaims beneficial ownership except for his pecuniary interest. The transaction was executed under a valid Power of Attorney filed previously with the SEC.
Immix Biopharma, Inc. (IMMX) filed a Form 4 on 23-Jun-2025 disclosing an equity award to insider Gabriel S. Morris, who serves as Director and Chief Financial Officer.
On 20-Jun-2025 Mr. Morris received 340,000 stock options with a $2.24 exercise price. The options vest in 48 equal monthly instalments and expire on 20-Jun-2035, signalling a long-term incentive structure tied to continued service.
Post-grant, Mr. Morris reports beneficial ownership of:
- 288,059 common shares held directly.
- 270,844 common shares held indirectly through Alwaysraise LLC.
- 24,141 common shares held indirectly through Alwaysraise Ventures I LP.
- 340,000 option shares newly awarded.
The filing shows no open-market purchases or sales; the transaction code “A” denotes an award. While the option grant introduces potential future dilution, it also aligns executive incentives with shareholder value creation over a ten-year horizon.
Form 4 Filing Details for Immix Biopharma (IMMX) reveals insider trading activity by Director Magda Marquet on June 20, 2025. The transaction involves the following key details:
- Acquisition of 33,000 stock options with exercise price of $2.24 per share
- Options expire on June 20, 2035
- Vesting schedule: 12 equal monthly installments from grant date
- Current holdings: 46,092 shares held directly and 20,000 shares held indirectly through ALMA Life Sciences, LLC
This stock option grant appears to be part of the company's director compensation program. The options provide Marquet with the right to purchase IMMX shares at $2.24 through 2035, aligning the director's interests with long-term shareholder value.
On 06/20/2025, Immix Biopharma (IMMX) director Jason Hsu filed a Form 4 disclosing a single insider transaction. The company issued Hsu a stock option covering 33,000 shares with a strike price of $2.24 per share. The option vests in twelve equal monthly installments from the grant date and expires on 06/20/2035, conditional on his continued service on the board.
After the award, Hsu reports total beneficial ownership of 4,861,913 common shares, broken down as: 893,000 shares held directly; 3,915,913 shares indirectly through Veritas Liberabit Vos, LLC; and 50,000 shares indirectly through Signature Collection Properties, LLC. No sales or dispositions occurred in this filing.
The incremental 33,000-share option grant represents less than 1 % of Hsu’s existing stake and does not materially alter the company’s capital structure. While the transaction reinforces management-shareholder alignment, its small size suggests limited immediate market impact.
Helen C. Adams, Director of Immix Biopharma (IMMX), reported the following insider trading activity on June 28, 2025:
- Received a stock option grant to purchase 33,000 shares of common stock at an exercise price of $2.24 per share
- The options were granted on June 20, 2025, with an expiration date of June 20, 2035
- Vesting schedule: Equal monthly installments over 12 months, contingent on continued board service
- Currently holds 174,754 shares of common stock directly
This Form 4 filing reflects standard board compensation practices through equity grants. The transaction was executed pursuant to the company's director compensation program, with the options granted at fair market value.
Immix Biopharma, Inc. (IMMX) – Form 4 insider filing dated 06/23/2025
Director Jane Buchan reported one equity award and updated share ownership as of 06/20/2025:
- New derivative grant: 33,000 non-qualified stock options with an exercise price of $2.24 per share, expiring 06/20/2035. The options vest in 12 equal monthly installments beginning on the grant date, contingent on continued service (Note 1).
- Post-transaction ownership: 22,455 shares of common stock held directly. No common shares were bought or sold in the reported period; the table only updates the total beneficial ownership.
No cash consideration was paid for the option grant (price listed as $0.00), indicating a routine director compensation award. The filing does not disclose any simultaneous open-market transactions, earnings data, or major corporate events.
Investors should note that while option grants can create future dilution if exercised, the 33,000-share award is relatively small and vests over one year, spreading potential dilution. The filing aligns the director’s incentives with shareholder value but, by itself, does not signal immediate changes to Immix Biopharma’s financial outlook.
Form 4 filing overview for Immix Biopharma (IMMX) discloses insider equity activity by CEO, Chairman and Director Ilya M. Rachman.
On 06/20/2025 the executive received an option grant covering 340,000 shares of common stock at an exercise price of $2.24 per share. The option expires on 06/20/2035 and vests in 48 equal monthly instalments, contingent upon continued service. The transaction is coded “A,” indicating an acquisition directly from the issuer, typically as equity compensation.
After the grant, Rachman reports holding 1,138,437 shares of common stock and 340,000 derivative securities (the newly issued options), all in direct ownership.
- No open-market purchase or sale of common stock occurred; the filing pertains solely to the new option award.
- The grant aligns executive incentives with long-term share performance but introduces potential future dilution if exercised.
The filing was signed on 06/23/2025.
Immix Biopharma, Inc. (IMMX) – Form 4 filed 06/23/2025
The filing discloses one transaction by Director and 10% owner Yekaterina (Katie) Chudnovsky dated 06/20/2025. She received a stock-option grant for 33,000 shares of common stock with an exercise price of $2.24 per share and an expiration date of 06/20/2035. The option vests in twelve equal monthly installments, contingent on continued board service. The option was acquired at no cost (transaction code “A”).
No non-derivative shares were bought or sold; the filing merely repeats her existing indirect ownership of 3,241,076 common shares held through GKCC, LLC, of which she is the sole member and manager. After the reported transaction, her total beneficial holdings stand at 3,241,076 shares (indirect) plus 33,000 derivative securities (direct).
Overall, the filing signals continued alignment between the director and shareholders through a sizeable existing stake and modest additional option incentives. The transaction does not materially alter the company’s share count or insider ownership structure.
FAQ
What is the current stock price of Immix Biopharma (IMMX)?
What is the market cap of Immix Biopharma (IMMX)?
What is the primary focus of Immix Biopharma?
What makes their CAR-T technology unique?
Which diseases are targeted by their product candidates?
How does Immix Biopharma ensure the safety and efficacy of its therapies?
What regulatory designations have their therapies achieved?
How does Immix Biopharma differentiate itself in the competitive cell therapy market?
Who are the likely customers or beneficiaries of these therapies?
What role do clinical trials play in their development strategy?
